Drug company Watson Laboratories (Actavis) has notified rival Ranbaxy Laboratories that it has applied to sell a generic version of anti-acne product Absorica in the US.
Medical device makers Boston Scientific and OrbusNeich announced on September 17 that they have settled all stent-related patent litigations.
Eli Lilly has filed a NOA against the Canadian government, alleging recent decisions that invalidated patents covering its Zyprexa and Strattera drugs were in breach of NAFTA.
The Indian government has awarded more than two thirds of its recent pharmaceutical patents to foreign drug makers, according to data released by the Indian Patent Office.
The Health Ministry in India has recommended that a compulsory licence is issued for the manufacture of Bristol-Myers Squibb’s anti-cancer drug Sprycel (dasatinib), potentially opening the door to the sale of cheaper imitations.
UK biopharmaceuticals company PolyTherics has completed a takeover of Antitope, a provider of antibody engineering and immunogenicity screening services.
The annual International Association for the Protection of Intellectual Property conference in Helsinki has been assessing the potential problems for pharmaceutical companies trying to brand their medicinal products.
Law firm Rouse has teamed up with two organisations to open the BioEconomy Academy, an initiative aimed at boosting IP use and awareness in Thailand.
The American Civil Liberties Union and other groups have submitted an amici curiae brief in support of Ambry Genetics and Gene by Gene in their patent infringement cases with Myriad Genetics Inc.
UK IP firm Marks & Clerk LLP has announced two of its attorneys will be joining the firm’s partnership.